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OBJECTIVES We sought to examine the effects of long-term vasopeptidase inhibition in patients with heart
failure.
BACKGROUND The long-term effects of omapatrilat, an agent that inhibits both neutral endopeptidase and
angiotensin-converting enzyme, on clinical status, neurohormonal indexes and left ventricular
function in patients with chronic heart failure (CHF) have not been previously documented.
METHODS Forty-eight patients in New York Heart Association functional class II or III, with left
ventricular ejection fraction (LVEF) #40% and in sinus rhythm were randomized to a
dose-ranging pilot study of omapatrilat for 12 weeks. Measurements were performed at
baseline and 12 weeks.
RESULTS There was an improvement in functional status, as reported by the patient (p , 0.001) and
physician (p , 0.001) at 12 weeks. Dose-dependent improvements in LVEF (p , 0.001) and
LV end-systolic wall stress (sigma) (p , 0.05) were seen, together with a reduction in systolic
blood pressure (p , 0.05). There was evidence of a natriuretic effect (p , 0.001), and total
blood volume decreased (p , 0.05). Omapatrilat induced an increase in postdose plasma atrial
natriuretic peptide levels (p , 0.01) in the high dose groups, with a reduction in predose
plasma brain natriuretic peptide (p , 0.001) and epinephrine (p , 0.01) levels after 12 weeks
of therapy. Omapatrilat was well tolerated.
CONCLUSIONS The sustained hemodynamic, neurohumoral and renal effects of omapatrilat, together with
improved functional status, suggest that vasopeptidase inhibition has potential as a new
therapeutic modality for the treatment of CHF. (J Am Coll Cardiol 2000;36:479–86) ©
2000 by the American College of Cardiology
Congestive heart failure is a complex syndrome triggered by
left ventricular (LV) dysfunction and includes neurohu-
moral changes, altered sodium and water handling and
increased peripheral resistance. The renin–angiotensin sys-
tem (RAS) is activated progressively as cardiac function
deteriorates, and inhibition of angiotensin-converting en-
zyme (ACE) decreases morbidity and mortality (1,2). The
cardiac natriuretic peptides are elevated early in chronic
heart failure (CHF) and may play a protective role (3), in
part through antagonism of the RAS. Previous studies have
shown that further increasing natriuretic peptide levels by
the short-term administration of exogenous atrial natriuretic
peptide (ANP) has potentially beneficial effects in patients
with congestive heart failure (4,5). By contrast, ANP
deletion in genetic ANP receptor “knockout” models or
antagonism of ANP by HS-142 in experimental settings
causes exacerbation of cardiac impairment and accelerated
heart failure (6,7). However, neutral endopeptidase (NEP)
inhibitors, which impede degradation of endogenous natri-
uretic peptides, have not gained credence as therapy in
congestive heart failure (8). This may partly reflect the
deleterious effects from activation of RAS and sympathetic
nervous systems associated with pure NEP inhibition (9).
Omapatrilat, a vasopeptidase inhibitor, is a single mole-
cule that simultaneously inhibits both NEP and ACE (10).
In animal studies, vasopeptidase inhibitors have been shown
to decrease LV end-diastolic pressure and peripheral vascu-
lar resistance, with an increase in cardiac output, compared
with selective inhibitors of ACE and NEP alone (11).
Omapatrilat improves LV remodeling and survival in car-
diomyopathic hampsters, compared with equipotent doses
of a selective ACE inhibitor (12). We investigated the
long-term effects of this novel agent in a dose-ranging pilot
study in patients with CHF.
METHODS
Study objectives. The primary objective was to assess the
effect of 12 weeks of treatment with omapatrilat on clinical
status, LV function, neurohormones, blood volume and
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renal function. The secondary objective was to document
the safety and tolerability of sustained omapatrilat therapy.
Study design. Approval for this single center, noninvasive
substudy was provided by the Canterbury Ethics Commit-
tee of the Health Funding Authority of New Zealand, and
all patients gave written, informed consent. Patients re-
cruited were concurrently enrolled in either 1) a 12-week
multicenter, double-blind, randomized, invasive hemody-
namic trial (n 5 40); or 2) a 12-week multicenter, double-
blind, randomized exercise trial (n 5 8) (13). Both studies
had a dose-ranging design with an active low dose (2.5 mg
of omapatrilat) control group. The 2.5-mg dose was chosen
as an active control therapy because in healthy male subjects
it has been shown that 2.5 mg of omapatrilat caused
significant ACE inhibition over 24 h, but, by contrast to
higher doses of omapatrilat, no significant NEP inhibition,
as measured by changes in urinary ANP and urinary second
messenger, cyclic 39,59-guanosine monophosphate (cGMP)
(14). Forty-eight patients in New York Heart Association
(NYHA) functional class II or III congestive heart failure,
with a left ventricular ejection fraction (LVEF) #40% and
in sinus rhythm, were enrolled. All ACE inhibitors and
angiotensin II receptor antagonists were stopped at least
four days before baseline measurements and for the entire
study period of 12 weeks. All other cardiac medications
were continued throughout the study. The protocol allowed
for up to four supplemental doses of furosemide (over 24 h)
for worsening heart failure during the 12 weeks of the trial.
However, if an increase in the maintenance dose was
necessary, patients were withdrawn from the study. After
baseline measurements, the patients were randomized to
one of five omapatrilat doses: 2.5, 5, 10, 20 or 40 mg/day for
12 weeks. Patients underwent an outpatient review at one,
two, four, six and eight weeks. At 12 weeks, measurements
were repeated on therapy four h after the final dose of
omapatrilat.
Methodology. All measurements were performed in a
quiet laboratory maintained at a constant temperature be-
tween 22°C and 25°C at midday. Patients abstained from
food, caffeine-containing drinks and cigarettes; this fasting
lasted for at least 4 h before measurement. M-mode and
two-dimensional echocardiographic studies were performed
in the left lateral recumbent position using a Hewlett-
Packard 1500 Sonos with a 2.5 MHz transducer. Cardiac
volumes were measured at end diastole (defined as the onset
of the Q wave on the electrocardiogram) and end systole
(defined as the first high frequency component of the aortic
second heart sound as measured by phonocardiography) in
three cardiac cycles, and the mean values were computed.
The LVEF was measured from the apical four-chamber
view by the single-plane ellipsoid method (15). Stroke
volume was measured by the LV outflow method using
pulsed wave Doppler echocardiography (average of five
cardiac cycles) (16).
Digital applanation tonometry (Millar Instruments,
Houston, Texas) of the left radial artery was performed for
8 s and calibrated to the brachial sphygmomanometric
blood pressure obtained at the time of pulse recording.
Using a generalized transfer function (PWV Medical, Syd-
ney, Australia), the mean ascending aortic systolic pressure,
mean diastolic pressure, end-systolic pressure and waveform
were derived (17,18). We used simultaneous M-mode or
pulsed wave Doppler echocardiography and digital appla-
nation tonometry to derive LV meridional end-systolic wall
stress (sigma) (19,20), rate-corrected velocity of circumfer-
ential fiber shortening (20), total peripheral resistance (21)
and myocardial oxygen demand as measured by the rate–
pressure product (22). All echocardiographic measurements
were performed by a single operator who had no knowledge
of the group allocation of the patients. The mean intrapa-
tient variability (repeatability) for observations in three
patients each repeated on three consecutive days showed a
coefficient of variation of 4.2% for LV internal dimension at
end systole, 9.8% for ejection fraction, 4.8% for end-systolic
pressure and 7.1% for stroke volume. Functional class
(NYHA) was assessed at baseline and 12 weeks. The
clinician’s and subject’s assessment of the change in func-
tional status at three months, compared with baseline, was
determined by a global assessment scale: improved (greatly,
moderately or slightly), unchanged or worsened.
Venous blood and blood volumes were measured from a
subgroup, as part of the concomitant hemodynamic study
during the hospital period, for right heart catheterization at
baseline and 12 weeks. Venous blood was drawn with the
patient lying quietly while semirecumbent at baseline before
the first dose of omapatrilat and at 3 h, 12 h and 24 h after the
first dose of the drug for measurements of plasma ANP and
cGMP. These were repeated after the final dose of the drug at
12 weeks. Venous blood was also drawn at baseline (predose)
and at 12 weeks for ANP, brain natriuretic peptide (BNP),
endothelin, catecholamines and aldosterone. Samples were
taken into chilled EDTA vacutainers, placed immediately on
ice and centrifuged within 20 min at 24°C, and the plasma
was stored at 280°C for assay (23–27). The endothelin
extraction method was the same as for ANP (23).
Endothelin-1 was assayed by adding 100 ml of plasma extract
or standard to 100 ml of diluted endothelin-1 antiserum
(Peninsula Laboratories, Belmont, California) with cross
reactivities of 100% for endothelin-1, 17% for human big
endothelin, 7% for endothelin-2, 7% for endothelin-3 and
Abbreviations and Acronyms
ACE 5 angiotensin-converting enzyme
ANP 5 atrial natriuretic peptide
BNP 5 brain natriuretic peptide
cGMP 5 cyclic 39,59-guanosine monophosphate
CHF 5 chronic heart failure
LVEF 5 left ventricular ejection fraction
NEP 5 neutral endopeptidase
NYHA 5 New York Heart Association
RAS 5 renin–angiotensin system
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0% for ANP. The assay was incubated for 3 h at room
temperature, after which 100 ml of iodine-125–
endothelin-1 (10,000 cpm) was added and incubated for 22
to 24 h at 4°C. Bound and free endothelin-1 was separated
by a solid-phase second antibody method, and the precipi-
tates were countered for radioactivity. The recovery rate of
endothelin-1 from human plasma was 91% at 36 pmol/liter,
and extracts of human plasma were diluted in parallel with
the standard curve. The assay had a mean detection limit of
1.4 pmol/liter over 30 assays. The intra-assay coefficient of
variation was 6.25%, and the interassay coefficient of vari-
ation was 16.4% at 2.5 pmol/liter.
Plasma volume was measured by the indocyanine green
dilution technique, with indocyanine green (0.25 mg/kg)
injected into the right heart catheter and venous blood
withdrawn 3 to 12 min after the injection from the opposite
arm (28).
Total blood volume 5
PV
1 2 ~Hct @0.91#!
where Hct 5 hematocrit (29) and PV 5 plasma volume.
Measurements of renal function were performed in a
subgroup of patients as part of the concomitant hemody-
namic study at baseline and 12 weeks. Patients were placed
on bed rest for $12 h before the start of collection (which
was begun immediately after administration of drug) and
throughout the 24-h urine collection period at baseline and
at 12 weeks. Urine volume and sodium and creatinine levels
were measured. Medications other than the study drug were
withheld over this period. Both oral fluids and solids were
regulated over the period of collection.
Statistical analysis. Changes from baseline to three
months for all subjects grouped together were assessed using
the paired t test. The dose groups are as follows: 2.5 mg as
the active control group, 5 to 10 mg as the low dose group
and 20 to 40 mg as the high dose group. We used two-way
analysis of variance with repeated measures to explore the
relation between the variable and dose group, followed by
Tukey’s test to explore pairwise differences when this
showed significant effects (p , 0.05). Analysis of variance
for hormonal and renal data was performed after logarith-
mic transformation, with mean absolute values given in the
Results section. Clinician and subject assessment of the
change in heart failure status at three months was analyzed
by using the Mann-Whitney U test, and differences be-
tween the variable and dose group by using the Kruskal-
Wallis test. Categoric variables were assessed by using the
Fisher exact test. Group data are expressed as the mean
value 6 SEM.
RESULTS
Forty-eight patients were randomized. The baseline char-
acteristics are shown in Table 1. Seven patients discontin-
ued therapy before 12 weeks. Three patients were with-
drawn from the 12-week study in the 2.5-mg group owing
to worsening heart failure (20%), compared with one patient
in the 5- to 10-mg group (5%) and none in the 20- to
40-mg group. Two patients (one in the 20- to 40-mg group
and one in 5- to 10-mg group) did not wish to return for the
concomitant 12-week hemodynamic study, and one patient
in the 20- to 40-mg group developed septicemia after
catheterization and was withdrawn. Forty-one patients
completed the 12-week study.
Clinical status. There were six hospital admissions for
worsening heart failure during the study. All but one of
these patients (5 to 10 mg) was in the 2.5-mg active control
group. In the 2.5-mg group, there were 27 episodes in 10
Table 1. Baseline Clinical Characteristics
Total (n 5 48)
Study Group
Omapatrilat Dose
2.5 mg
(n 5 15)
5–10 mg
(n 5 18)
20–40 mg
(n 5 15)
Age in years (range) 67 (49–86) 67 (58–80) 70 (49–86) 66 (56–76)
Male 90% 92% 81% 100%
Creatinine in mmol/liter (range) 0.11
(0.06–0.18)
0.11
(0.07–0.18)
0.11
(0.06–0.16)
0.12
(0.09–0.16)
Presumed etiology of heart failure
Ischemic 83% 93% 83% 86%
Idiopathic cardiomyopathy 11% 7% 11% 7%
Hypertension 6% 0% 6% 7%
NYHA functional class
II 58% 53% 61% 60%
III 42% 47% 39% 40%
Treatment
ACE inhibitors 85% 87% 89% 80%
Angiotensin II blockers 10% 13% 0% 20%
Diuretics 94% 93% 94% 93%
Digoxin 29% 20% 33% 33%
Beta-blockers 14% 13% 11% 20%
Data are presented as the mean value 6 SEM or percentage of patients.
ACE 5 angiotensin-converting enzyme; NYHA 5 New York Heart Association.
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patients (66.7% of group) requiring supplemental doses of
furosemide; in the 5- to 10-mg dose, there were three
episodes in three patients (16.7%), and one episode in the
20- to 40-mg group (6.7%). There was significantly less
need for supplementary furosemide in the 20- to 40-mg
group, and the 5- to 10-mg group (both p , 0.01), as
compared with the 2.5-mg control group.
There was an improvement in NYHA functional class at
12 weeks in the 20- to 40-mg group (39% improving by one
functional class), compared with the 2.5-mg group (0%)
(p , 0.05), but no difference between the 5- to 10-mg
group (23%) and the 2.5-mg control group.
At 12 weeks, the patients’ score for functional status had
improved (p , 0.001) (Table 2). There was significantly
greater improvement with the 5- to 10-mg doses (p ,
0.001) and 20- to 40-mg doses (p , 0.001), compared with
the 2.5-mg dose. The clinician’s 12-week score for the
patients’ heart failure status also indicated overall improve-
ment (p , 0.001). Again, improvement was more pro-
nounced in the higher dose groups compared with the
2.5-mg control group (p , 0.05).
Tolerability. Four patients developed first-dose symptom-
atic hypotension in the 20- to 40-mg group, which resolved
spontaneously. One of these patients had intermittent
symptomatic hypotension throughout the study, but was
able to continue. Five other patients (three in the 20- to
40-mg group and two in the 5- to 10-mg group) had
episodes of symptomatic hypotension which resolved with a
reduction in furosemide maintenance dose, with no deteri-
oration in NYHA functional class. No reduction in furo-
semide maintenance dose was undertaken in the 2.5-mg
control group. One patient developed a dry cough during
the second week, which resolved spontaneously by six
weeks. Overall, the drug was well tolerated.
LV systolic function: change from baseline to 12 weeks
for all 41 patients combined (Table 3). There was a small
fall in heart rate (p , 0.05). The LVEF improved (p ,
0.001), with no significant change in end-diastolic volume,
but a reduction in end-systolic volume (p , 0.01). The
stroke volume index increased slightly (p , 0.05), with no
significant change in cardiac output or cardiac index. Myo-
cardial oxygen demand, as measured by the rate–pressure
product, fell (p , 0.0001). Both systolic (p , 0.0001) and
diastolic (p , 0.05) brachial blood pressures fell, along with
total peripheral resistance (p , 0.001).
Dose-related changes over 12 weeks (Table 4). Baseline
variables were not significantly different between the groups.
Table 2. Assessment of Change in Heart Failure Status
Omapatrilat Dose
2.5 mg
(n 5 15)
5–10 mg
(n 5 17)
20–40 mg
(n 5 13)
n % n % n %
Patient assessment at 12 weeks
Greatly improved 0 0 7 41 5 38
Moderately improved 5 33 6 35 5 38
Slightly improved 3 20 1 6 2 15
No change 2 13 2 12 1 8
Worsened 5 33 1 6 0 0
Clinician rating at 12 weeks
Greatly improved 0 0 2 12 2 15
Moderately improved 0 0 7 41 9 69
Slightly improved 8 53 6 35 2 15
No change 1 7 1 6 0 0
Worsened 6 40 1 6 0 0
Table 3. Change in LV Function, Brachial Blood Pressure,
24-h Urine Values and Blood Volume Over 12 Weeks
(All Patients Combined)
Baseline 12 Weeks p Value
HR (beats/min) 71 6 2.3 67 6 1.8 , 0.05
EDV (ml) 322 6 17 311 6 16 NS
ESV (ml) 247 6 14 226 6 14 , 0.001
LVEF (%) 24 6 1.0 28 6 1.2* , 0.001
LV meridional wall stress
(g/cm2)
156 6 9 137 6 12* 0.2
Vcfc (circ/s) 0.43 6 0.02 0.48 6 0.04 0.2
SVI (m/m2) 32 6 1.5 34 6 1.8 , 0.05
CI (liter/min per m2) 2.28 6 0.11 2.4 6 0.14 NS
RPP (beats.mm Hg per
min)
87 6 2.9 71 6 2.2 , 0.0001
Brachial SBP (mm Hg) 131 6 3.2 116 6 3.5* , 0.0001
Brachial DBP (mm Hg) 73 6 1.8 68 6 1.8 , 0.05
TPR (mm Hg per liter) 25 6 1.3 21 6 1.1 , 0.001
Urine volume (ml) 1,796 6 134 2,147 6 130 , 0.001
Urine sodium (mmol) 111 6 11 135 6 10* , 0.01
Creatinine clearance (ml/s) 1.45 6 0.1 1.36 6 0.06 NS
Plasma creatinine
(mmol/liter)
0.10 6 0.003 0.10 6 0.003 NS
Blood volume (liter) 6.26 6 0.29 5.89 6 0.32 , 0.05
*Significant dose-dependent improvement. Data are presented as mean value 6 SEM.
CI 5 cardiac index; DBP 5 diastolic blood pressure; EDV 5 end-diastolic
volume; ESV 5 end-systolic volume; HR 5 heart rate; LV 5 left ventricular;
LVEF 5 left ventricular ejection fraction; RPP 5 rate–pressure product; SBP 5
systolic blood pressure; SVI 5 stroke volume index; TPR 5 total peripheral
resistance; Vcfc 5 rate-corrected velocity of circumferential fiber shortening.
Table 4. Dose-Related Changes Over 12 Weeks
Omapatrilat Dose
2.5 mg 5–10 mg 20–40 mg
EDV (ml) 219.3 6 7.3 20.3 6 15.3 217 6 8.3
ESV (ml) 24.6 6 8.5 221.0 6 11.7 234.1 6 4.2
LVEF (%) 23.4 6 1.7 6.7 6 1.6† 7.4 6 1.0†
CI (liter/min per m2) 20.0 6 0.1 0.1 6 0.2 0.2 6 0.2
SBP (mm Hg) 23.6 6 4.6 216.8 6 6.1 225 6 4.5*
DBP (mm Hg) 1.6 6 2.8 27.5 6 3.6 28.4 6 2.8
MAP (mm Hg) 20.2 6 3.0 210.6 6 4.2 214.0 6 3.0*
TPR (mm Hg/min
per liter)
245.7 6 131 2416.6 6 164 2445.8 6 116
RPP (beats.mm Hg
per min)
210.1 6 4.5 215.5 6 4.5 220.8 6 4.8
Vcfc (circumference/s) 0.059 6 0.056 0.022 6 0.07 0.085 6 0.078
LV meridional wall
stress (g/cm2)
29.5 6 29.6 233.6 6 19.8 261.5 6 13.6*
Urine volume (ml) 259 6 215 302 6 186 478 6 129
Urine sodium (mmol) 12.1 6 7.1 14.1 6 14 47.2 6 12*
Blood volume (ml) 82 6 317 2170 6 415 2749 6 164
*p , 0.05 vs. 2.5-mg dose. †p , 0.01 vs 2.5-mg dose. All measurements are presented
as the mean (6SEM) change from baseline to day 82, except for 24-h urine volume
and sodium measurements (change from day 1 to day 83).
Abbreviations as in Table 3.
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There were no significant dose-related reductions in LV
volumes; however, LVEF showed a significant dose-
dependent improvement (p , 0.001). Systolic (p , 0.05),
diastolic (p 5 0.05) and mean arterial (p , 0.05) brachial
blood pressures all showed dose-dependent falls. Left ven-
tricular end-systolic meridional wall stress (sigma) also
showed changes between the groups (p , 0.05), with a
significant fall in the 20- to 40-mg group (p , 0.05),
compared with the 2.5-mg control group, with a smaller fall
in the 5- to 10-mg group (p 5 NS). There was no change
in the rate-corrected velocity of circumferential fiber short-
ening at 12 weeks.
Renal function and blood volume (Tables 3 and 4).
Twenty-four-hour urine volume was higher at 12 weeks
(p , 0.001) compared with baseline, with no significant
difference between the groups. Urine sodium excretion was
also higher overall at 12 weeks (p , 0.01), with a dose-
related increase (p , 0.05), significantly more so in the 20-
to 40-mg group compared with the 2.5-mg group (p ,
0.05) and with the 5- to 10-mg group (p , 0.05). Plasma
creatinine level, creatinine clearance and patient weight
showed no significant change between the groups over 12
weeks.
Total blood volume for all groups was lower at 12 weeks
compared with baseline (p , 0.05), with a tendency for a
greater fall in the 20- to 40-mg group compared with the
2.5-mg group (p 5 0.09). Plasma hematocrit did not
change.
Neurohormones. High dose omapatrilat caused a prompt
and vigorous increase in plasma ANP after the first dose
(p 5 0.07 for group, p 5 0.2 for time, p , 0.05 for
interaction), with a significant increase in ANP at 3 h in the
high dose group compared with both the 2.5-mg group
(p , 0.01) and the 5- to 10-mg group (p , 0.05). Similar
early dose-dependent increases were seen with plasma
cGMP (p , 0.05 for group, p , 0.01 for time, p , 0.01 for
interaction) (Fig. 1A). Subsequently, ANP and cGMP fell
to near baseline levels.
After 12 weeks, high dose omapatrilat induced an in-
crease in ANP, compared with day 1 predose levels (p ,
0.05 for group, p 5 0.07 for time, p , 0.05 for interaction),
with a significant increase in the 20- to 40-mg group at 3 h
compared with both the 2.5-mg group (p , 0.01) and the
5- to 10-mg group (p , 0.05). At 12 h, the plasma ANP
remained greater in the 20- to 40-mg group compared with
the 5- to 10-mg group (p , 0.01). Similar increases were
seen at 12 weeks with cGMP (p 5 0.1 for group, p , 0.01
for time, p , 0.01 for interaction), with a significant
increase at 3 h in the high dose group compared with the
Figure 1. Graph showing the change in ANP and cGMP over 24 h for each group after the initial dose of omapatrilat (A) and after the final dose of
omapatrilat at 12 weeks (B). Data represent mean values 6 SEM. *p , 0.05. **p , 0.01 vs. 2.5-mg low dose control group.
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2.5-mg group (p , 0.01) and also in the 5- to 10-mg group
compared with the 2.5-mg group (p , 0.05) (Fig. 1B).
Neurohormones: change from baseline for all groups
combined (n 5 33) over 12 weeks (Table 5). There was
no change in predose plasma ANP levels over 12 weeks, but
plasma BNP levels had declined (p , 0.001) by 12 weeks.
Epinephrine levels in plasma fell over 12 weeks (p , 0.001),
whereas norepinephrine and endothelin-1 showed no sig-
nificant change. Aldosterone fell over the 12 weeks (p ,
0.01).
Neurohormones: change between the groups over 12
weeks (Table 6). There was no difference between the
groups in terms of change in plasma levels of ANP from
predose day 1 to predose week 12. The BNP level fell in all
groups over 12 weeks. Endothelin-1 was significantly lower
in the 20- to 40-mg group compared with both the 5- to
10-mg group (p , 0.001) and the 2.5-mg group (p , 0.01)
at baseline. Over 12 weeks, there was a significant fall in
endothelin-1 in the 5- to 10-mg group compared with the
20- to 40-mg group (p , 0.01), with no difference between
the 2.5-mg group and the 20- to 40-mg group. There were
no differences between the groups in terms of epinephrine,
norepinephrine and aldosterone levels over 12 weeks.
DISCUSSION
The vasopeptidase inhibitors are a new class of drug with
therapeutic potential in heart failure. Animal studies show
that the potentially beneficial effects of NEP inhibition may
be attenuated by activation of RAS, but ACE inhibition in
combination with NEP inhibition can restore the physio-
logic action of ANP in experimental heart failure (30).
Omapatrilat is the first vasopeptidase inhibitor to be studied
in patients with CHF.
Because of the clearly established benefits of ACE inhi-
bition in CHF, no placebo group was included on the basis
of ethical grounds, and higher doses of vasopeptidase
inhibition (NEP plus ACE inhibition) were compared with
the 2.5-mg dose, which has been reported to inhibit ACE
but not NEP (14).
Effects on clinical status and tolerability. Overall, oma-
patrilat had beneficial effects, as evidenced by improvement
in clinical status over three months, with a dose-dependent
reduction in episodes of acute heart failure. Omapatrilat was
well tolerated, with transient symptomatic hypotension seen
only at higher doses. This was readily managed by a diuretic
reduction and did not require discontinuation of the drug.
In this study, unlike in clinical practice, there was no
stepwise increase in the dosage, and the results confirm that
dose titration would be appropriate on commencing the
drug. No episodes of angioedema were seen.
Effect on LV function. The improvement in ejection
fraction was dose-dependent. Left ventricular systolic per-
formance is predominantly dependent on preload, myocar-
dial contractility and afterload. An inverse relation exists
between the mean velocity of circumferential fiber shorten-
ing and LV end-systolic wall stress (20). This relation is
sensitive to the altered contractile state, is independent of
preload, incorporates both afterload and heart rate and can
be accurately determined by noninvasive means without
manipulation of loading conditions (20). We have shown
both a fall in myocardial oxygen consumption, as shown by
the rate–pressure product, and a dose-dependent reduction
in afterload. Despite a significant improvement in LVEF,
there was no increase in the contractile state, as measured by
the rate-corrected velocity of circumferential fiber shorten-
Table 5. Change in Predose Neurohormones Over 12 Weeks
(All Groups Combined)
Baseline
(Predose)
12 Weeks
(Predose) p Value
ANP (pmol/liter) 68 6 6 67 6 8 NS
BNP (pmol/liter) 50 6 5 40 6 4 , 0.001
Endothelin-1
(pmol/liter)
2.4 6 0.1 2.2 6 0.1 NS
Epinephrine
(pmol/liter)
159 6 18 99 6 10 , 0.01
Norepinephrine
(pmol/liter)
2,407 6 141 2,317 6 146 NS
Aldosterone
(pmol/liter)
247 6 26 193 6 23 , 0.01
Data are presented as the mean value 6 SEM.
ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic peptide.
Table 6. Dose-Related Changes in Neurohormone Levels Over
12 Weeks
Variable
Omapatrilat Dose
p Value*2.5 mg 5–10 mg 20–40 mg
ANP predose,
day 1
69 6 10 77 6 8 52 6 10 NS
ANP predose,
week 12
61 6 8 72 6 13 64 6 18 NS
BNP predose,
day 1
61 6 9 43 6 5 42 6 10 NS
BNP predose,
week 12
54 6 8† 40 6 4 34 6 9‡ NS
ET-1 predose,
day 1
2.6 6 0.2 2.8 6 0.2 1.7 6 0.2 , 0.001
ET-1 predose,
week 12
2.4 6 0.1 2.4 6 0.1‡ 1.9 6 0.2 , 0.01
EPI predose,
day 1
144 6 29 178 6 38 154 6 23 NS
EPI predose,
week 12
95 6 26 88 6 13‡ 118 6 14† NS
NE predose,
day 1
2,680 6 290 2,263 6 218 2,271 6 204 NS
NE predose,
week 12
2,650 6 237 2,087 6 252 2,284 6 251 NS
ALD predose,
day 1
303 6 54 200 6 29 246 6 53 NS
ALD predose,
week 12
187 6 32‡ 198 6 36 193 6 51 NS
*Significant difference between groups. †p , 0.05 within group. ‡p , 0.01 within
group compared with predose day 1. Data are presented as the mean value 6 SEM
in pmol/liter.
ALD 5 aldosterone; ANP 5 atrial natriuretic peptide; BNP 5 brain natriuretic
peptide; EPI 5 epinephrine; ET-1 5 endothelin-1; NE 5 norepinephrine.
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ing, and no deleterious increase in estimated myocardial
oxygen demand. Left ventricular performance, as measured
by the relation between end-systolic wall stress (sigma) and
rate-corrected velocity of circumferential fiber shortening,
was enhanced in the higher dose groups, secondary to a
reduction in afterload. In the absence of changes in LV
preload (i.e., end-diastolic volume), we were unable to
detect a protective effect against LV remodeling with 12
weeks of treatment.
In previous studies, pure NEP inhibition did not induce
a sustained reduction in systolic blood pressure (8,31,32).
However, omapatrilat induced a dose-dependent reduction
in systolic and diastolic blood pressure, with a fall in total
peripheral vascular resistance, suggesting an effect of com-
bined inhibition of ACE and NEP not observed with the
pure NEP inhibitors candoxatril or sinorphan (8,31,32).
Effects on renal function and blood volume. The baseline
24-h urine measurements were started with the administra-
tion of the first dose of omapatrilat, whereas concomitant
medications, including diuretics, were withheld for 24 h.
Normally, withdrawal of diuretics produces a powerful
antidiuresis (33). Natriuretic peptides (3,4) and pure NEP
inhibitors (31,34) induce natriuresis, and we found that
there was greater sodium and volume excretion over 24 h at
the 12-week study compared with baseline, both days on
which diuretics were withheld. This change in urine indexes
after 12 weeks of therapy with omapatrilat may reflect
changes in intrarenal sodium-conserving mechanisms, due
to enhanced local action of ANP, and reduced activity of
sympathetic and renin-angiotensin-aldosterone systems, as
reflected in reduced plasma epinephrine and aldosterone
levels. In contrast, it is unlikely that a negative daily balance
of water and sodium existed throughout the 12-week study
without adverse consequences. Importantly, there was pres-
ervation of renal function with no deterioration in creatinine
clearance over the three months, despite the sizeable decline
in arterial pressure and blood volume.
Previous studies (35) have shown that other vasodilators
modify regional blood flow, with a change in apparent
plasma and blood volume. Pure NEP inhibitors have been
suggested as alternatives to diuretics. To our knowledge, our
data include the first measurements of blood volume after
12-week therapy for congestive heart failure. It is likely that
the reduction in blood volume is partly due to an increase in
urinary fluid and sodium loss. Atrial natriuretic peptide
given in the short term causes contraction of blood volume
by inducing a shift from vascular to extravascular space (36).
However, we did not see a change in hematocrit over 12
weeks of combined ACE and NEP inhibition to support
this. Further mechanistic studies of the fall in blood volume
with vasopeptidase inhibition are required.
Effect on neurohormones. Ideally, therapeutic interven-
tions in heart failure should produce favorable effects on
both hemodynamic and neurohormonal systems. The ben-
eficial hemodynamic changes seen in this study with oma-
patrilat were paralleled by improvement in the neurohor-
monal profile. Inhibition of NEP by omapatrilat in patients
with heart failure was demonstrated by increased plasma
ANP and cGMP after initial (higher) doses of omapatrilat.
In contrast, early treatment with pure ACE inhibition has
been shown to cause a fall in ANP (37,38). Subsequently,
ANP levels fell to near baseline levels over the 24 h,
consistent with reduced ANP secretion, presumably second-
ary to improved hemodynamic data. With long-term ther-
apy, the fall in predose BNP at 12 weeks presumably reflects
a reduction of LV wall stress and, consequently, a reduction
in BNP secretion, which overcame any tendency for NEP
inhibition to increase plasma BNP through reduced clear-
ance. In contrast, predose ANP levels after long-term
therapy are sustained. The likely mechanism underlying the
different responses of plasma ANP and BNP resides in
NEP’s greater affinity for ANP than BNP (39) (i.e., the
effect of reduced ANP secretion is perfectly balanced by
delayed clearance). Postdose increments in plasma ANP and
cGMP with higher doses were similar at day 1 and after 12
weeks of long-term therapy at day 83, mitigating against
tolerance of NEP’s inhibitory effect with long-term treat-
ment.
There was no evidence for activation of the sympathetic
nervous system over 12 weeks in response to the significant
falls in blood pressure. Rather, a reduction in heart rate and
plasma epinephrine suggests that sympathetic activity might
have been attenuated. Unchanged plasma norepinephrine
also mitigates against generalized activation of the sympa-
thetic nervous system, possibly due to a sympathoinhibitory
effect of ANP with higher omapatrilat doses (40,41).
Reduced epinephrine over 12 weeks may reflect reduced
adrenal sympathetic nervous system traffic in response to
beneficial hemodynamic changes and perhaps a fall in
angiotensin II levels.
Study limitations. This study lacks a true placebo limb.
Full withdrawal of ACE inhibition is not appropriate. The
use of an active control group may have resulted in under-
estimation of dose-related changes. The groups do allow
comparison of low dose vasopeptidase inhibition (ACE
inhibition only) with high dose effects (ACE and NEP
inhibition). The hemodynamic improvements seen may be
due to increasing ACE inhibition with higher doses. How-
ever, the rise in plasma ANP and cGMP with higher doses
is consistent with NEP inhibition.
Conclusions. In this first report of long-term treatment
with a vasopeptidase inhibitor in patients with symptomatic
heart failure, omapatrilat induced a dose-dependent im-
provement in both functional and hemodynamic status.
Plasma ANP is increased relative to BNP, which fell over
the long term, presumably reflecting a reduction in LV wall
stress, the primary secretory stimulus for this peptide. The
improvements in functional status are paralleled by im-
provements in hemodynamic status, with reductions in
afterload, arterial pressure and central blood volume. The
data suggest enhanced excretion of sodium and water, with
no deterioration of renal function. We conclude that higher
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doses of omapatrilat appear to have effects due to both ACE
inhibition and ANP augmentation. On the basis of these
results, this drug is suitable for larger comparative trials with
morbidity and mortality end points. Omapatrilat may be a
significant new therapy in the treatment of CHF.
Reprint requests and correspondence: Prof. Hamid Ikram, De-
partment of Cardiology, Christchurch Hospital, Private Bag 4710,
Christchurch, New Zealand. E-mail: HAMIDI@chhlth.govt.nz.
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